Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW3811 in Advanced Solid Tumors
NCT05911984Phase 1Unknown
- Sponsor
- Mabwell
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 9MW3811 in solid tumor (advanced stage), sponsored by Mabwell. Primary endpoints: Incidence of adverse events (AEs) at 24 weeks and Incidence of dose-limiting toxicity (DLT). Status: unknown.
02
Drugs
9MW3811
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05911984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911984.